EUCTR2012-003560-49-GB进行中（未招募）1 期
A PHASE II, RANDOMISED, SINGLE CENTRE, OPEN-LABEL, TWO-ARM STUDY TO DETERMINE THE SAFETY AND EFFICACY OF BUPRENORPHINE ORAL LYOPHILISATE (XPRENOR ®) IN COMPARISON WITH BUPRENORPHINE SUBLINGUAL TABLETS (SUBUTEX®)IN OPIOID-DEPENDENT PATIENTS - Safety & Efficacy of 2 Alternative Forms of Oral Buprenorphine (v10)
Macarthys Laboratories Limited (trading as Martindale Pharma)0 个研究点目标入组 36 人开始时间: 2012年8月28日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Clinical condition: Opioid-dependent patients, eligible for opioid substitution therapy.
- •2. Gender: Male and Female.
- •3. Age: =18 - =60 years.
- •4. BMI: =18.0 to =30.0 Kg/m2.
- •5. Capable of providing voluntary informed consent.
- •6. For female subjects of child-bearing potential an adequate form of contraception must be adhered to for at least 30 days prior to trial entry however, this requirement may be waived if there have been two negative serum pregnancy tests at least seven days apart before being dosed with buprenorphine (e.g. at screening and prior to the first buprenorphine dose). The patient must adhere to a contraceptive regimen continuously until 30 days after the last Extension Period visit.
- •Adequate contraception is defined as:
- •a. The usage by the female subject/partner of any hormonal contraception or intra-uterine device (which should be established prior to the start of the trial), plus usage by at least one of the partners of an additional spermicide-containing barrier method of contraception.
- •b. The use of a barrier method alone or abstinence is not considered adequate.
- •c. Females of non-child-bearing potential i.e., postmenopausal, must be amenorrhoeic for at least 2 years AND have a serum follicle stimulating hormone (FSH) level of at least 30 IU/L, or have undergone a hysterectomy or bilateral oophorectomy (tubal ligation is not acceptable).
- •7. A non-custodial stable residence and telephone number.
- •8. For patients enrolling in the pharmacokinetic part of the study venous access must be suitable for the collection of serial blood samples. All other subjects should have venous access adequate for the collection of all required study samples using conventional techniques.
- •9. No treatment with either buprenorphine or methadone within one day of receiving study treatment. If potential study subjects do not meet this criterion patients can enter a Pre-randomisation Management Period. During this period buprenorphine and methadone will be excluded for at least one day. Where necessary, interim treatment with oral morphine (either as slow-release or standard oral immediate release morphine) will be provided.
- •10. The screening ECG should be normal or have no clinically significant abnormalities.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 36
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Hypersensitivity to buprenorphine or any other component of the oral lyophilisate.
- •2. Dependent use of cocaine and amphetamines requiring specific treatment
- •3. .Regular use of other opioids from 24 hours prior to the first dose of buprenorphine until the end of the study.
- •4. Severe hepatic insufficiency (defined as liver function tests, including alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase, greater than three times the upper limit of normal).
- •5. Patients suffering from severe respiratory insufficiency.
- •6. Patients suffering from acute alcoholism or delirium tremens.
- •7. Habitual or dependent use of benzodiazepines, which may potentiate respiratory depression, above recommended therapeutic doses or patients who are taking benzodiazepines erratically.
- •8. Concomitant medication known to interact with buprenorphine.
- •9. Administration of any approved or investigational long-acting injections of antipsychotic medications.
- •10. Current psychiatric diagnosis of major depression with suicidal ideation, psychosis, bipolar disorder, or any psychiatric disorder that would compromise the patient's ability to complete the study.
- •11. Female patients with a positive pregnancy test, lactating mother, women refusing to agree to adequate contraception and pregnancy tests during the study, or women who are planning to become pregnant during the period of the trial.
- •12. Participation in a clinical trial of a pharmacological agent within 6 months of screening.
- •13. Any other factor that in the opinion of the Investigator would make the patient unsafe or unsuitable for the study.
研究者
相似试验
进行中（未招募）
1 期
A PHASE II, OPEN LABEL, RANDOMISED, SINGLE CENTRE STUDY TO EVALUATE THE SAFETY, REACTOGENICITY AND IMMUNOGENICITY OF THREE OR FOUR DOSES OF MENINGOCOCCAL SEROGROUP B OUTER MEMBRANE VESICLE (OMV) VACCINE MENZBTM WHEN ADMINISTERED TO HEALTHY ADULTS (UNIVERSITY STUDENTS)Prevention of invasive disease caused by N. meningitidis serogroup BEUCTR2005-003570-22-GBHealth Protection Agency
进行中（未招募）
1 期
A PHASE II, MULTICENTRE, RANDOMISED, OPEN-LABEL, ACTIVE CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MICAFUNGIN SALVAGE MONO THERAPY VERSUS ACTIVE CONTROL INTRAVENOUS SALVAGE MONO THERAPY IN PATIENTS WITH INVASIVE ASPERGILLOSIS - Micafungin Salvage Mono Therapy in Invasive AspergillosisEUCTR2005-004988-27-BEAstellas Pharma BV135
进行中（未招募）
1 期
A PHASE II, MULTICENTRE, RANDOMISED, OPEN-LABEL, ACTIVE CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MICAFUNGIN SALVAGE MONO THERAPY VERSUS ACTIVE CONTROL INTRAVENOUS SALVAGE MONO THERAPY IN PATIENTS WITH INVASIVE ASPERGILLOSIS - Micafungin Salvage Mono Therapy in Invasive AspergillosisPatients with haematopoietic stem cell transplantation (HSCT), acute leukaemia, myelodysplastic syndrome (MDS) and with proven (probable only in case of pulmonary aspergillosis) invasive aspergillosis and who are also refractory or intolerant to previous systemic antifungal therapy. Criteria for refractoriness and intolerance are defined in Appendix III of the study protocol.MedDRA version: 8.1Level: LLTClassification code 10022881Term: Invasive bronchopulmonary aspergillosisEUCTR2005-004988-27-HUAstellas Pharma BV135
进行中（未招募）
1 期
A PHASE II, MULTICENTRE, RANDOMISED, OPEN-LABEL, ACTIVE CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MICAFUNGIN SALVAGE MONO THERAPY VERSUS ACTIVE CONTROL INTRAVENOUS SALVAGE MONO THERAPY IN PATIENTS WITH INVASIVE ASPERGILLOSIS - Micafungin Salvage Mono Therapy in Invasive AspergillosisPatients with haematopoietic stem cell transplantation (HSCT), acute leukaemia, myelodysplastic syndrome (MDS) and with proven (probable only in case of pulmonary aspergillosis) invasive aspergillosis and who are also refractory or intolerant to previous systemic antifungal therapy. Criteria for refractoriness and intolerance are defined in Appendix III of the study protocol.MedDRA version: 8.0Level: LLTClassification code 10022881EUCTR2005-004988-27-ESAstellas Pharma GmbH135
进行中（未招募）
不适用
A PHASE II, MULTICENTRE, RANDOMISED, OPEN-LABEL, ACTIVE CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MICAFUNGIN SALVAGE MONO THERAPY VERSUS ACTIVE CONTROL INTRAVENOUS SALVAGE MONO THERAPY IN PATIENTS WITH INVASIVE ASPERGILLOSIS - Micafungin Salvage Mono Therapy in Invasive AspergillosisPatients with haematopoietic stem cell transplantation (HSCT), acute leukaemia, myelodysplastic syndrome (MDS) and with proven (probable only in case of pulmonary aspergillosis) invasive aspergillosis and who are also refractory or intolerant to previous systemic antifungal therapy. Criteria for refractoriness and intolerance are defined in Appendix III of the study protocol.MedDRA version: 8.1Level: LLTClassification code 10022881Term: Invasive bronchopulmonary aspergillosisEUCTR2005-004988-27-DEAstellas Pharma BV135